Teva Pharmaceutical Cash Flow - Annual (NYSE:TEVA)

Add to My Stocks
$23.99 $0.02 (0.08%) TEVA stock closing price Jun 22, 2018 (Closing)

The Teva Pharmaceutical cash flow statement helps investors understand how well the company is managing its cash flows. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For Teva Pharmaceutical profits one has to check the income statement and for Teva Pharmaceutical debt one has to check the balance sheet. Teva Pharmaceutical cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. Teva Pharmaceutical had cash and cash equivalents of $988M at the beginning of the year and $963M at year end for 2017. Teva Pharmaceutical had an inflow of $3.51B from operating activities, $-5.75B spend due to financing activities, and $2.16B inflow due to investing activities for 2017.

View details of Teva Pharmaceutical cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Net Income Cash Flow
-16.45B311M1.6B3.04B1.25B1.91B2.77B3.34B2B635M
Depreciation Depletion Amortization Cash-Flow2.11B1.52B1.31B1.51B1.64B1.71B1.07B977M908M493M
Net Increase (Decrease) in Assets Liabilities-363M1.22B967M290M968M414M597M-253M445M76M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net18.21B2.17B1.67B287M-626M540M-300M73M16M2.03B
Net Cash from (used by) Operating Activities
3.51B5.23B5.54B5.13B3.24B4.57B4.13B4.14B3.37B3.23B
Increase (Decrease) in Prop Plant And Equipment2.6B1.1B-248M-733M-844M-840M-774M-710M-719M-681M
Acquisition Disposition of Subsidiaires43M-36.15B-3.31B-363M-39M--6.56B-4.95B--4.75B
Increase (Decrease) in Investments-200M-481M-2B-324M-160M-201M-217M177M-197M1.23B
Other Cash Inflow (Outflow) from Investment Activities-282M-212M-5M-30M-104M-93M-49M29M-67M
Net Cash from (used by) Investment Activities
2.16B-35.74B-5.57B-1.45B-1.15B-1.13B-7.6B-5.46B-916M-4.14B
Issuance (Purchase) of Equity Shares-364M3.24B14M-406M-1.15B-828M-99M169M192M
Issuance (Repayment) of Debt Securities-2.79B24.58B2.87B-839M-2.8B2.81B5.16B520M120M-258M
Increase (Decrease) in Bank & Other Borrowings-1.68B2B29M-385M384M-2.49B-124M626M-2B1.78B
Payment of Dividends & Other Cash Distributions-1.16B-1.56B-1.16B-1.16B-1.09B-855M-800M-668M-528M-388M
Other Cash from (used by) Financing Activities-112M-169M-178M-9M23M5M-70M194M-24M32M
Net Cash from (used by) Financing Activities
-5.75B25.22B4.81B-2.38B-3.88B-1.68B3.34B573M-2.27B1.36B
Effect of Exchange Rate Changes on Cash54M-660M-62M-114M-48M23M-21M-1M-51M-86M
Net Change in Cash & Cash Equivalents
-25M-5.96B4.72B1.19B-1.84B1.78B-152M-747M141M366M
Cash & Equivalents at Beginning of Year988M6.95B2.23B1.04B2.88B1.1B1.25B2B1.85B1.49B
Cash & Equivalents at Year End963M988M6.95B2.23B1.04B2.88B1.1B1.25B2B1.85B
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Teva Pharmaceutical stock price history provides insight into historical stock price fluctuations, and Teva Pharmaceutical stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Teva Pharmaceutical has cash of $963M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Teva Pharmaceutical stock price.
  • The cash generated from the core business or operations was a positive at $3.51B for Teva Pharmaceutical in the latest 2017. For an internet company, this would include all those activities which are involved in eventually selling advertisement space on its website or any online service.
  • Cash Flow from investment activities: Teva Pharmaceutical generated $2.16B cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash flow from financing activities shows the flow of cash between Teva Pharmaceutical and its owners and creditors and was $-5.75B for 2017. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Teva Pharmaceutical Cash Flow

FCF margin
0.43

Annual Cash Flow Statements For Teva Pharmaceutical Industries Ltd (ADR) Peers

Allergan cash flow, Astrazeneca cash flow, Eagle Pharma cash flow, Fortress Biotech cash flow, Mylan cash flow